The Rise of PJ.2.1 and BA.3.2
The variant currently attracting the most recent attention is PJ.2.1, first detected in Ontario, Canada, in May 2026. Described by researchers as a “saltation” variant—meaning it emerged with a large number of genetic changes rather than gradual accumulation—PJ.2.1 has since been identified in multiple U.S. states, including New York, California, and Florida, as well as in Australia, New Zealand, and several European countries. Public Health Ontario data indicates that PJ.2.1 accounted for 25.2% of sequenced SARS-CoV-2 samples in late September and early October 2026, up from 16.9% in the preceding four weeks, signaling a rapid increase in its circulation.
Concurrently, the BA.3.2 variant (“Cicada”), first identified in late 2024, has established a widespread presence, detected in at least 23 countries and half of U.S. states. While BA.3.2 was linked to hospitalizations earlier in the year, it is not currently the dominant strain in most regions, though its spread highlights the continuous evolution of the virus.
Spike Protein Mutations and Immune Evasion
The clinical significance of these variants hinges on their spike proteins, which bind to human cells. Recent research published in the Journal of Infection suggests that PJ.2.1’s increased transmissibility is linked more closely to enhanced binding to the ACE2 receptor than to a substantial ability to evade vaccine-induced antibodies. However, lab studies on BA.3.2 have shown that current vaccines, which target the JN.1 lineage, may be less effective against this specific strain. Despite this, experts note that the vaccines are not rendered obsolete. “It’s not completely clear how effective the current vaccine will be, but it likely still has some effectiveness,” said E. Antonio García-Sastre, a virologist. The World Health Organization and the CDC maintain that current vaccines continue to provide protection against severe disease, even if their efficacy against mild infection may vary.
Symptom Overlap and Diagnostic Challenges
One of the most significant practical challenges for patients and providers is the lack of distinct clinical features that separate these new variants from other seasonal respiratory illnesses. Symptoms reported for recent infections include fever, cough, sore throat, shortness of breath, and congestion. Some physicians have also noted an increase in gastrointestinal issues, such as nausea, vomiting, and diarrhea, particularly associated with the XFG (“Stratus”) variant, which has been circulating since early 2025. In some cases, patients have reported red or itchy eyes and unusually painful sore throats.
Dr. Greeta Sood, an epidemiologist at Johns Hopkins Bayview Medical Center, emphasized that “there is not really a distinct trait between these respiratory illnesses.” Because influenza and respiratory syncytial virus (RSV) are also circulating, symptom-based diagnosis is frequently inaccurate. Health authorities strongly recommend testing to confirm infection and determine appropriate treatment, as the standard of care for severe cases relies on accurate identification of the pathogen.
Public Health Impact and Prevention
Despite the spread of these new lineages, the overall severity of the current wave appears lower than previous surges. CDC data indicates that while case rates are increasing in most states, the percentage of positive tests and emergency room visits remain lower than in previous years. More than 5,800 COVID-19 deaths have been recorded in the U.S. this year, a figure that, while serious, is part of a broader trend of declining mortality compared to earlier pandemic peaks.
Experts caution that the return of children to school and increased indoor social mixing could drive further transmission. However, antiviral therapies remain effective against the new variants. Dr. Celine Gounder, a public health editor, noted, “We haven’t seen evidence of this variant causing more severe disease or an increase in hospitalizations elsewhere.”
Recommendations and Future Outlook
Public health guidance remains focused on high-risk groups. Adults over 65, individuals with underlying conditions such as heart disease, lung disease, or diabetes, and those who are immunocompromised are advised to consider vaccination. The CDC recommends getting a current dose of the vaccine, particularly towards the end of summer, to provide protection against potential autumn and winter peaks. Updated vaccines are expected to become available in the fall, potentially offering broader coverage against emerging strains.
For the general population, preventive measures include testing when symptomatic, staying home when sick, and wearing masks in crowded indoor settings. As the virus continues to adapt to human immune defenses, scientists expect further evolution. The coming months will be critical for determining whether these new variants alter the disease’s severity profile or if the current immunity landscape remains sufficient to prevent a resurgence of severe illness.
One Comment